At a glance
- Originator Pfizer
- Class Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 03 Jul 2000 Profile reviewed but no significant changes made
- 06 Dec 1996 No-Development-Reported for Neurological disorders (Prevention) in USA (Unknown route)